Joe Renda News Today

Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.29824 EPS, expectations were $0.09. Amneal Pharmaceuticals, Inc.

The Frehleys Comet bassist died in April 2023. Just three days before his untimely passing, he spoke to Bass Player about his remarkable career, including the highs and lows of working with Ace Frehl

Ongentys (opicapone) is an adjunctive therapy for the treatment of Parkinson’s disease.

ONGENTYS® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s DiseaseComplements Amneal’s existing Parkinson’s franchise and further expands specialty portfolioBRIDGEWATER, N.J. & PORTO, Portugal--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela &...

07.12.2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone) in the U.S. starting on ... Seite 1

Anthony DiMeo: Good morning, and thank you for joining Amneal Pharmaceuticals Third Quarter 2023 Earnings Call. Today, we issued a press release reporting our Q3 results.

Operator: Hello, everyone and welcome to the Amneal Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Bruno, and I’ll be operating your call today.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2023 Earnings Call Transcript August 4, 2023 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.19, expectations were $0.1. Operator: Hello, everyone and welcome to the Amneal Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Bruno, and I’ll be operating your call today. [Operator Instructions] I will […]